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In vitro efﬁcacy of tyrosine kinase inhibitors:
SYK and BCR-ABL inhibitors in lymphomas
To the Editor
The B cell receptor (BCR) signalling pathway is believed
to play a major role in B cell lymphoma growth and
survival [1,2]. SYK is a critical non-receptor tyrosine
kinase involved in the BCR signalling, that, when
activated, leads to intracellular calcium mobilization,
activation of AKT, mitogen-activated protein kinases and
NFkB. A relatively strong expression of SYK can be
demonstrated in the vast majority of non-Hodgkin
lymphoma subtypes [3], and inhibition of SYK has been
shown as a new promising therapeutic approach for
lymphoid neoplasms [4–8]. Here, we report new in vitro
data on the activity of different SYK inhibitors in
lymphoma cell lines and lymphoma primary cells.
Based upon our previous data on mantle cell lymphoma
(MCL) cell lines [4], we ﬁrst treated six diffuse large B cell
lymphomas (DLBCL) cell lines (Karpas 422, VAL,
SUDHL-6, OCI Ly19, U2392 and DOHH2) with increas-
ing doses of the SYK inhibitor piceatannol (3,4,30,50-
tetrahydroxy-trans-stilbene; Sigma, Fluka Chemie GmbH,
Buchs, Switzerland) for 72 h (Figure 1A). Cell growth
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Figure 1. (A) Cytotoxic effect of piceatannol on DLBCL cell lines. Cells were exposed for 72 h to the indicated concentration of the
drug. Y-axis, percentage of viable cells. X-axis, doses of piceatannol in mM. Error-bars represent the standard deviation calculated for at
least 12 replicates derived from three different experiments. Viable cell number was determined by measuring 3-(4,5-dimethylthiazol-
2-yl)-2,5-dimethyltetrazolium bromide (MTT) dye absorbance as previously described [4,17]. (B) Basal levels of SYK in DLBCL cell lines
and demonstration of the presence of an extra-copy of the gene by FISH. Upper panel: Immunoblotting showing SYK protein
expression. Lower panel: FISH analysis using BAC targeting SYK region (red) metaphases of SUD-HL-6 DLBCL cell line. FISH was
performed as previously described [4]
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inhibition was observed: the 50% inhibitory concentrations
(IC50) were 18mM in SUDHL-6, 25mM in U2392, 37mM
in DOHH2, 48mM inKarpas 422 and higher than 50mM in
OCI-Ly19 and in VAL. SUDHL-6, which was the most
sensitive and that showed a clear dose–response, was the
cell linewith the highest level of SYK at protein level and it
presented an extra-copy of the locus containing SYK,
as shown by ﬂuorescence in situ hybridization (FISH)
(Figure 1B). In SUDHL6, the cell growth inhibition was
due to apoptosis induction, as shown by Western blotting
with antibodies speciﬁc for the cleaved form of poly (ADP-
ribose) polymerase (PARP) (Figure 2A). Treatment of the
MCL cell line Jeko1 and of DLBCL cell line SUDHL-6
with the corresponding IC50 doses of piceatannol
determined a reduction of the levels of total cellular
phospho-tyrosine residues at 24, 48 and 72 h (Figure 2B),
showing that indeed the activity of piceatannol might be
mediated by a reduction in tyrosines phosphorylation, as
described in chronic myeloid leukaemia (CML) after
treatment with imatinib [9].
Three of the six DLBCL cell lines and the four MCL cell
lines (NCEB-1, REC, Granta-519 and JeKo-1) [4] were
then exposed to increasing doses of a potent SYK/ZAP7
inhibitor, NVP, for 72 h. Only the two cell lines expressing
high levels of SYK, JeKo-1 and SUD-HL-6, showed an
IC50 of 1mM, a dose used to block mast cell degranulation
without affecting cell viability [10], suggesting a SYK-
mediated cytotoxic effect. The MCL cell line Granta-519
had a similar IC50, but the inhibitory effect was not evident
at higher doses, while Karpas 422 had an IC50 of 5mM.
VAL, Rec and NCEB1 were not sensitive to the compound
at doses up to 25mM.
Due to the suggested capacity of the BCR-ABL
inhibitor imatinib to bind SYK [11], the MCL and
DLBCL cell lines were exposed to increasing doses of
the two BCR-ABL inhibitors imatinib and nilotinib
already in the clinical setting. No cell line responded
to doses of imatinib lower than 12.5mM, thus beyond
the concentration clinically achievable and used for
CML and other sensitive neoplasms [12–15]. Still,
JeKo-1 and SUD-HL-6 showed progressive inhibition
of cell proliferation reaching the IC50 at a dose of 15–
20mM, indicating a possible dose-dependent cytotoxic
effect in the two cell lines with constitutively high SYK
levels.
To obtain further data on the relevance of SYK
inhibition in lymphoma, we treated ﬁve lymphoma primary
cells derived from DLBCL and three from leukaemic
MALT lymphomas with increasing doses of NVP and
piceatannol (0, 2, 5 and 10mM) and with nilotinib at the
clinically reachable [16] dose of 2mM. A dose of 10mMof
piceatannol induced at least 50% reduction of cell
proliferation in four DLBCL, but had no effect on the
remaining primary cells. NVP induced more than 50%
cytotoxicity in 2/3 MALT lymphoma samples at a dose of
2mM, while DLBCL primary cells did not respond.
Nilotinib induced more than 50% decrease of the viable
cell number in 1/3 MALT lymphomas and in 1/5 DLBCL
samples. These data obtained on lymphoma primary cells
conﬁrmed the cytotoxic activity of tyrosine kinase
inhibitors in lymphoma primary cells, but the heterogenous
pattern of response suggested that the effect was not
necessarily mediated by SYK inhibition, but it could be
due to inhibition of other molecules contributing to the
constitutive BCR signalling.
In conclusion, our functional characterization of SYK in
lymphoma cell lines and lymphoma primary cells support
the design of prospective trials testing different molecules
targeting SYK.
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Figure 2. (A) Effect of piceatannol on the induction of apoptosis
in SUDHL-6. Apoptosis was detected by immunoblotting with an
antibody directed against the cleaved form of PARP in untreated
control cells (-) and in cells treated (þ) for 12 and 24 h with IC50
dose of piceatannol, as previously described [17]. Tubulin was
used as a control for sample loading (lower panel). (B) Effect of
piceatannol on total cellular level of phospho-tyrosine on MCL
and DLBCL cell lines. Phospho-tyrosines were detected by
immunoblotting with P-Tyr-100 antibody (Cell Signaling Tech-
nology, Danvers, MA, USA) directed against any phospho-Tyr
residues in a manner largely independent of the surrounding
amino acid sequence of the individual proteins. -, untreated
control cells; þ, cells treated for 48 h with IC50 dose of picea-
tannol. Tubulin was used as a control for sample loading
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